Differential toxicity of protease inhibitors in cultures of cerebellar granule neurons.
Involvement of proteases has been postulated in several neurodegenerative processes. Accordingly, protease inhibition has been proposed as a potential therapeutic tool to limit damage in some neuropathological states. The timed turn-over of proteins is, however, an essential biochemical process and its prolonged block may be dangerous to the cell. We report here data on toxicity consequent to 24-h exposure of cerebellar granule neurons in culture to inhibitors of different classes of proteases. Inhibition of calpains (calcium-activated cysteine proteases) resulted in dose-dependent neuronal death which largely occurred through apoptotic process. Leupeptin, an inhibitor acting on a broad spectrum of cellular serine proteases, was less toxic but resulted in definite morphological alteration of the cells. On the contrary, inhibitors of caspases, proteases belonging to the ICE (interleukin 1-beta converting enzyme) family, did not apparently damage granule neurons upon exposure for 24 h to high concentrations (up to 200 microM) of two inhibitors specific for ICE (Ac-YAVD-CHO) and CPP-32 (Ac-DEVD-CHO), respectively. These results suggest that inhibition of proteases that are activated by stressful stimuli but are not essential for the normal functioning of healthy cells, as it is likely the case for caspases, may not be harmful to neurons. Instead, the potential risks and side effects of prolonged inhibition of proteases such as calpains, that regulate the disposal and the turn-over of key cellular proteins, should be carefully tested in the assessment of possible neuroprotective roles.
Monti
B
B
Department of Biology, University of Bologna, Bologna, I-40126, Italy.
Sparapani
M
M
Contestabile
A
A
D000818:Animals; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology; D002478:Cells, Cultured; D002531:Cerebellum / Q000166:cytology*; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology; D004151:Dipeptides / Q000494:pharmacology; D020287:In Situ Nick-End Labeling; D007770:L-Lactate Dehydrogenase; D007976:Leupeptins / Q000494:pharmacology; D009474:Neurons / Q000166:cytology / Q000187:drug effects*; D009842:Oligopeptides / Q000494:pharmacology; D011480:Protease Inhibitors / Q000633:toxicity*; D051381:Rats; D017208:Rats, Wistar
D015853:Cysteine Proteinase Inhibitors; D004151:Dipeptides; D007976:Leupeptins; D009842:Oligopeptides; D011480:Protease Inhibitors; C099158:acetyl-aspartyl-glutamyl-valyl-aspartal; C071482:calpeptin; D007770:L-Lactate Dehydrogenase; C032854:leupeptin